Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Cir. Urug ; 7(1): e304, 2023. ilus
Article in Spanish | LILACS, UY-BNMED, BNUY | ID: biblio-1505950

ABSTRACT

El manejo del adenocarcinoma de recto se ha visto revolucionado por la cirugía mesorectal y la neoadyuvancia al igual que el cáncer epidermoide de ano con el protocolo de Nigro. Sin embargo, los adenocarcinomas de ano constituyen una patología infrecuente, relacionada con procesos inflamatorios crónicos como las fístulas perianales y cuyo tratamiento genera controversias. El desconocimiento de sus características clínicas e imagenológicas puede generar una confusión diagnóstica principalmente con un absceso perianal. Presentamos el caso clínico de un adenocarcinoma de canal anal en relación a una fístula perianal crónica y una revisión de la literatura actual sobre el tema.


The mesorectal surgery and the neoadyuvant treatment have changed the management of rectal adenocarcinoma. The Nigro protocol had the same impact on the squamous cell cancer of the anus. However, the adenocarcinoma of the anus is an infrequent pathology, related to chronic inflammatory processes such as perianal fistulas and its treatment generates controversy. The lack of knowledge about clinical and imaging characteristics of this pathology can lead to diagnostic confusion, mainly with a perianal abscess. We hereby present the clinical case of an anal canal adenocarcinoma in relation to a chronic perianal fistula and a review of the current literature on the subject.


O manejo do adenocarcinoma retal foi revolucionado pela cirurgia mesorretal e pelo tratamento neoadjuvante, assim como o câncer de células escamosas do ânus com o protocolo Nigro. Entretanto, os adenocarcinomas do ânus são uma patologia pouco frequente, relacionada a processos inflamatórios crônicos como as fístulas perianais e cujo tratamento gera controvérsias. O desconhecimento de suas características clínicas e de imagem pode levar a uma confusão diagnóstica, principalmente com o abscesso perianal. Apresentamos o caso clínico de um adenocarcinoma do canal anal relacionado a uma fístula perianal crônica e uma revisão da literatura atual sobre o assunto.


Subject(s)
Humans , Male , Aged , Anal Canal/pathology , Anus Neoplasms/diagnostic imaging , Adenocarcinoma, Mucinous/diagnostic imaging , Anus Neoplasms/radiotherapy , Palliative Care , Rectal Fistula , Fatal Outcome , Adenocarcinoma, Mucinous/radiotherapy
2.
Rev. bras. cancerol ; 59(1): 81-86, jan.- mar. 2013.
Article in Portuguese | LILACS | ID: lil-722810

ABSTRACT

Introdução: O adenocarcinoma mucinoso é uma rara neoplasia formada por células apócrinas da pele hipersecretoras de muco. Pálpebras, couro cabeludo e outras regiões da cabeça e do pescoço são os sítios primários mais acometidos. Relatodo caso: Os autores descrevem o caso de uma lesão suspeita em couro cabeludo, cuja excisão e análise confirmaram um adenocarcino mamucinoso de anexo cutâneo. Mesmo após a ressecção, surgiram lesões metastáticas nas regiões retroauricular, cervical, supraclavicular e couro cabeludo. Fez-se, então, quimioterapia e radioterapia. Meses depois, a paciente relatou dor na coluna e no braço com irradiação para a mão e parestesias. Após exames, confirmou-se metástaseem linfonodos axilares, em ossos da coluna vertebral, com iminente compressão medular. A radioterapia, então, foi realizada nessas regiões. A paciente apresentou melhora significativa e mantém acompanhamento. Conclusão: O adenocarcinoma mucinoso é uma rara neoplasia e as características do relato apresentado tornam-no ainda mais raro. O diagnóstico da doença exige uma correlação clínica, radiológica e patológica. Quando submetidos a tratamento precoce, os pacientesapresentam um bom prognóstico com raras chances de metástases, embora recidivas sejam comuns.


Subject(s)
Humans , Female , Adenocarcinoma, Mucinous/diagnosis , Adenocarcinoma, Mucinous/drug therapy , Adenocarcinoma, Mucinous/radiotherapy , Neoplasm Metastasis , Neoplasms/drug therapy , Neoplasms/radiotherapy , Recurrence
3.
Indian J Cancer ; 2011 Jan-Mar; 48(1): 24-30
Article in English | IMSEAR | ID: sea-144407

ABSTRACT

Background : 5-Flourouracil (FU)-based chemotherapy (CT) and concurrent 45 Gy radiotherapy (RT) is one of the standard postoperative approaches currently used in gastric carcinoma. The high toxicity rates of this treatment leads to interruption of treatment in the majority of patients. In our study, we investigated the rates of toxicity and treatment discontinuation observed during postoperative FU-based chemoradiotherapy (CRT); retrospectively evaluated the effect of CRT and the other prognostic factors on local and distant control and survival. Patients and Methods: A total of 160 patients consisting of 97 total and 63 subtotal gastrectomy receiving postoperative CRT, have been studied retrospectively. Results : Patients who had to discontinue the treatment for a median of 6 (range, 3-13) days experienced toxicity during treatment at a rate of 43%. During the 21 (range, 4-68) months of follow-up local recurrences were observed in 8 (5%) patients and distant recurrences were observed in 41 (25.6%) patients. While the 1-3 year overall survival (OS) rates were 75% and 42%, 13-year disease-free survival (DFS) rates were 63% and 42%, respectively. In the univariate analysis for OS and DFS demonstrated statistical significance for below those 60 years of age, D1-D2 dissection type, negative surgical margin, early treatment beginning, the absence of invasion, and early stage disease. D1D2 dissection type, early treatment begining, age below 60 years and early stage disease significantly improve OS and DFS in multivarite analysis. Conclusions: Survival is worse in patients older than 60 years, had late treatment begining, advanced stage and D0 dissection.


Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/radiotherapy , Adenocarcinoma/therapy , Adenocarcinoma, Mucinous/drug therapy , Adenocarcinoma, Mucinous/radiotherapy , Adenocarcinoma, Mucinous/therapy , Adult , Aged , Antimetabolites, Antineoplastic/therapeutic use , Carcinoma, Papillary/drug therapy , Carcinoma, Papillary/radiotherapy , Carcinoma, Papillary/therapy , Carcinoma, Signet Ring Cell/drug therapy , Carcinoma, Signet Ring Cell/radiotherapy , Carcinoma, Signet Ring Cell/therapy , Combined Modality Therapy , Female , Fluorouracil/therapeutic use , Follow-Up Studies , Gastrectomy , Humans , Male , Middle Aged , Retrospective Studies , Stomach Neoplasms/drug therapy , Stomach Neoplasms/radiotherapy , Stomach Neoplasms/therapy , Survival Rate , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL